BioSyent Inc.·Healthcare

MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 44,222 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company's Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date.

BioSyent Inc. (RX:CA) Q4 2025 Earnings Call Prepared Remarks Transcript

MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include:

MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 19, 2026 after market hours. A presentation on the Company's fourth quarter and full year 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.

MISSISSAUGA, Ontario, March 02, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) is pleased to announce that it has successfully closed the previously-announced acquisition of Oral Science Inc. (“Oral Science”), a privately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec.

Accretive Transaction with Combined Companies' Pro-Forma Revenue in Excess of $70.00 Million and EBITDA(1) in Excess of $15.75 Million (TTM Sept 30, 2025)
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Healthcare
Drug Manufacturers - Specialty & Generic
60
2012-02-22
0.65